as on February 28, 2026 at 7:59 am IST
Day's Low
Day's High
1.73%
Downside
3.04%
Upside
52 Week's Low
52 Week's High
37.82%
Downside
547.64%
Upside
Check Sarepta Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$1.8B
EPS (TTM)
4.3162
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
26.64%
PE Ratio (TTM)
276.74
Industry PE ratio
17.325641025641026
PEG Ratio
159.25
EBITDA
-605.4M
Revenue (TTM)
2.2B
Profit Margin
-32.45%
Return On Equity TTM
-53.47%
Track how Sarepta Therapeutics, Inc. P/E has moved over time to understand its valuation trends.
Sarepta Therapeutics, Inc. in the last 5 years
Lowest (-94.84x)
March 31, 2025
Industry (17.33x)
February 28, 2026
Today (276.74x)
February 28, 2026
Highest (110.59x)
September 30, 2024
Today’s Price to Earnings Ratio: 276.74x
Compare market cap, revenue, PE, and other key metrics of Sarepta Therapeutics, Inc. with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
|---|---|---|---|---|---|
| BUY | $1.8B | -80.75% | 276.74 | -32.45% | |
| BUY | $122.0B | 133.75% | 31.34 | 32.94% | |
| BUY | $43.9B | 124.79% | 142.78 | 8.45% | |
| NA | $35.7B | NA | 619.94 | 1.38% | |
| BUY | $81.5B | 73.48% | 18.59 | 31.41% |
The Sarepta Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Sarepta Therapeutics, Inc. investment value today
Current value as on today
₹19,995
Returns
Returns from Sarepta Therapeutics, Inc. Stock
Dollar Returns*
₹4,304 (+4.3%)
Based on 29 analysts
82.76%
Buy
17.24%
Hold
0.00%
Sell
Based on 29 analysts, 82.76% of analysts recommend a 'BUY' rating for Sarepta Therapeutics, Inc.. Average target price of $21.04
Get share price movements and forecasts by analysts on Sarepta Therapeutics, Inc..
What analysts predicted
20.39%UPSIDE
Target Price
$21.04
Current Price
$16.75
Analyzed by
29 Analysts
Target
$21.04
Sarepta Therapeutics, Inc. target price $21.04, a slight upside of 20.39% compared to current price of $16.75. According to 29 analysts rating.
Investment in Sarepta Therapeutics, Inc. Shares on INDmoney has grown by 16.93% over the past 30 days, indicating increased transactional activity.
Time period: to
Change:16.93% versus previous 30 day period
Search interest for Sarepta Therapeutics, Inc. Stock has decreased by -22% in the last 30 days, reflecting a downward trend in search activity.
Time period: to
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Today's Timeline - 26 February
Thu, 04:22 PM
-CEO Douglas Ingram plans to retire by end of 2026 amid company challenges and stock volatility concerns.
Thu, 08:00 PM
-Sarepta's Q4 revenue of $442.93 million beats estimates but reflects a significant year-over-year decline.
Thu, 08:59 PM
-Sarepta reports Q4 2025 adjusted loss of $3.58 per share, wider than estimates, with revenues down nearly 33% year-over-year.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Revenue Rich
![]()
Revenue is up for the last 2 quarters, 399.35M → 442.93M (in $), with an average increase of 9.8% per quarter
Against Peers
![]()
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 34.9% return, outperforming this stock by 119.2%
Against Peers
![]()
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 71.2% return, outperforming this stock by 160.2%
Price Dip
![]()
In the last 7 days, SRPT stock has moved down by -7.5%
Profit Down
![]()
Netprofit is down for the last 3 quarters, 196.89M → -412.22M (in $), with an average decrease of 160.2% per quarter
| Organisation | Sarepta Therapeutics, Inc. |
| Headquarters | 215 First Street, Cambridge, MA, United States, 02142 |
| Industry | Health Technology |
| CEO | Mr. Douglas S. Ingram Esq., J.D. |
| E-voting on shares | Click here to vote |
Name | Title |
|---|---|
Rachael Potter Ph.D. | Chief Scientific Officer |
Tamara Thornton | Director of Finance, Treasury & Investor Relations |
Dr. Diane L. Berry Ph.D. | Executive VP and Chief of Global Policy & Advocacy Officer |
Patrick Moss Pharm.D. | Executive VP & Chief Commercial Officer |
Mr. Douglas S. Ingram Esq., J.D. | CEO & Director |
Mr. Ian Michael Estepan | President & COO |
Dr. Louise R. Rodino-Klapac Ph.D. | President of Research & Development and Technical Operations |
Ryan H. Wong | Executive VP & CFO |
Ms. Cristin L. Rothfuss J.D. | Executive Vice President, General Counsel & Company Secretary |
Ms. Alison Nasisi | Executive VP & Chief People Officer |
Sarepta Therapeutics, Inc. share price today is $16.75 as on at the close of the market. Sarepta Therapeutics, Inc. share today touched a day high of $17.26 and a low of $16.46.
Sarepta Therapeutics, Inc. share touched a 52 week high of $108.48 on and a 52 week low of $10.42 on . Sarepta Therapeutics, Inc. stock price today i.e. is closed at $16.75,which is 84.56% down from its 52 week high and 60.83% up from its 52 week low.
Sarepta Therapeutics, Inc. market capitalisation is $0.00T as on .
Indian investors can start investing in Sarepta Therapeutics, Inc. (SRPT) shares with as little as ₹91.026 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹910.26 in Sarepta Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on ).
Based on Sarepta Therapeutics, Inc. share’s latest price of $16.75 as on February 28, 2026 at 2:29 am IST, you will get 0.5970 shares of Sarepta Therapeutics, Inc.. Learn more about
fractional shares .
Sarepta Therapeutics, Inc. stock has given -80.75% share price returns and 23.96% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?